Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Valeant Pharmaceuticals Intl (VRX) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 3,739,280
  • Shares Outstanding, K 347,840
  • Annual Sales, $ 9,674 M
  • Annual Income, $ -2,409 M
  • 36-Month Beta -0.20
  • Price/Sales 0.39
  • Price/Cash Flow 0.76
  • Price/Book 1.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.35 +3.86%
on 03/21/17
16.95 -36.58%
on 02/27/17
-5.43 (-33.56%)
since 02/24/17
3-Month
10.35 +3.86%
on 03/21/17
17.55 -38.75%
on 01/10/17
-3.60 (-25.09%)
since 12/23/16
52-Week
10.35 +3.86%
on 03/21/17
38.50 -72.08%
on 05/03/16
-20.34 (-65.42%)
since 03/24/16

Most Recent Stories

More News
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

CELG : 123.38 (+0.13%)
IBB : 290.06 (+0.37%)
GILD : 67.51 (+0.03%)
VRX : 10.75 (-1.01%)
AMGN : 165.74 (-0.18%)
Biotechs Focus on Improving Cancer Pain Management for Enhanced Patient Care

PALM BEACH, Florida, March 22, 2017 /PRNewswire/ --

QBIO : 4.4600 (-9.53%)
HTBX : 0.87 (unch)
PULM : 3.54 (-1.67%)
CPRX : 1.70 (+1.19%)
VRX : 10.75 (-1.01%)
Biotechs Focus on Improving Cancer Pain Management for Enhanced Patient Care

MarketNewsUpdates.com News Commentary

VRX.TO : 14.36 (-1.17%)
QBIO : 4.4600 (-9.53%)
PULM : 3.54 (-1.67%)
HTBX : 0.87 (unch)
CPRX : 1.70 (+1.19%)
VRX : 10.75 (-1.01%)
Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA

Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Bausch + Lomb announced that the FDA has set a PDUFA date on Aug 24 for its decision on the New Drug Application (NDA) for latanoprostene...

HSKA : 98.72 (+0.50%)
AERI : 45.85 (+0.55%)
VRX : 10.75 (-1.01%)
RTRX : 17.39 (-0.80%)
Valeant Completes Refinancing Transactions

- Extends Maturities of Term Loan Debt to 2022

VRX.TO : 14.36 (-1.17%)
VRX : 10.75 (-1.01%)
Jazz Sleep Disorder Drug Positive in Phase III Studies

Jazz Pharmaceuticals plc (JAZZ) recently announced positive efficacy results from two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110 for the treatment of excessive...

ABCO : 44.70 (unch)
JAZZ : 143.14 (+0.45%)
VRX : 10.75 (-1.01%)
ADUS : 30.70 (+0.99%)
Biotech Bull Making a Comeback

Biotech Bull Making a Comeback

CELG : 123.38 (+0.13%)
IBB : 290.06 (+0.37%)
GILD : 67.51 (+0.03%)
VRX : 10.75 (-1.01%)
AMGN : 165.74 (-0.18%)
Biotech Bull Making a Comeback

Biotech Bull Making a Comeback

CELG : 123.38 (+0.13%)
IBB : 290.06 (+0.37%)
GILD : 67.51 (+0.03%)
VRX : 10.75 (-1.01%)
AMGN : 165.74 (-0.18%)
Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that as of 5:00 p.m. New York City time on March 20, 2017 (the "Early Participation Date"),...

VRX.TO : 14.36 (-1.17%)
VRX : 10.75 (-1.01%)
Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod

Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that the U.S. Food and...

VRX.TO : 14.36 (-1.17%)
VRX : 10.75 (-1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients....

See More

Support & Resistance

2nd Resistance Point 11.05
1st Resistance Point 10.90
Last Price 10.75
1st Support Level 10.65
2nd Support Level 10.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.